Compare Inovio Pharmaceuticals Inc (INO) vs MobilEye Global Inc (MBLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs MobilEye Global Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while MobilEye Global Inc trades at $9.08 (market cap $7.54B). The key difference: MobilEye Global Inc is far larger — about 84.5× Inovio Pharmaceuticals Inc's market cap, and MobilEye Global Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | MBLY | |
|---|---|---|
Market Cap | $89.27M | $7.54B |
Sector | Health | Technology |
52-Week High | $2.87 | $16.19 |
52-Week Low | $1.05 | $6.56 |
Enterprise Value | $60.28M | $6.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Mobileye (MBLY) trades at $8.95, down 2.93% on the day, with a bearish technical signal and mixed earnings history. The company reported a net loss of $392 million in 2025 despite revenue of $1.89 billion, reflecting negative profit margins. Recent news highlights its strategic shift toward launching a vertically integrated U.S. robotaxi service in 2027, generating significant media attention and analyst coverage.
The outlook hinges on execution of its robotaxi initiative, offering growth potential but carrying high execution risk. Analyst consensus is bullish with a $10.71 price target, yet profitability challenges and competitive pressures pose substantial risks. Investors should weigh the long-term transformation against current financial weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →
